International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.
Abstract
This new classification strategy is based on a multidisciplinary approach to diagnosis of lung adenocarcinoma that incorporates clinical, molecular, radiologic, and surgical issues, but it is primarily based on histology. This classification is intended to support clinical practice, and research investigation and clinical trials. As EGFR mutation is a validated predictive marker for response and progression-free survival with EGFR tyrosine kinase inhibitors in advanced lung adenocarcinoma, we recommend that patients with advanced adenocarcinomas be tested for EGFR mutation. This has implications for strategic management of tissue, particularly for small biopsies and cytology samples, to maximize high-quality tissue available for molecular studies. Potential impact for tumor, node, and metastasis staging include adjustment of the size T factor according to only the invasive component (1) pathologically in invasive tumors with lepidic areas or (2) radiologically by measuring the solid component of part-solid nodules.
Keywords
computed tomography
molecular
EGFR
KRAS
EML4-ALK
gene profiling
gene amplification
surgery
limited resection
bronchioloalveolar carcinoma
lepidic
acinar
p63
papillary
micropapillary
solid
adenocarcinoma in situ
minimally invasive adenocarcinoma
colloid
mucinous cystadenocarcinoma
enteric
fetal
signet ring
clear cell
frozen section
TTF-1
p63.
lung
adenocarcinoma
classification
histologic
pathology
oncology
pulmonary
radiology
Domains
Cancer
Origin : Files produced by the author(s)